Patents by Inventor Dimitrios Stefanidis

Dimitrios Stefanidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20240316018
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Application
    Filed: February 27, 2024
    Publication date: September 26, 2024
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR
    Publication number: 20240277725
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.
    Type: Application
    Filed: April 5, 2024
    Publication date: August 22, 2024
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • Therapeutic compounds
    Patent number: 11993583
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: May 28, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Pharmaceutical compositions comprising a JAK inhibitor
    Patent number: 11975008
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I characterized by an XRPD pattern substantially the same as shown in FIG. 1 and uses thereof are described herein.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: May 7, 2024
    Assignee: GALAPAGOS NV
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11944611
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 2, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
  • Combination formulation of two antiviral compounds
    Patent number: 11707479
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: July 25, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE
    Publication number: 20220296619
    Abstract: Long-acting formulations comprising isopropyl ((S)—((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate, or a pharmaceutically acceptable salt thereof, and a biodegradable polymer, e.g. poly(lactic-co-glycolic acid) (PLGA), are described, as are methods of making the long acting formulations and uses thereof.
    Type: Application
    Filed: August 18, 2020
    Publication date: September 22, 2022
    Inventors: Jessica M. Bane, Elham Nejati, Dimitrios Stefanidis
  • Combination formulation of three antiviral compounds
    Patent number: 11338007
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 24, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20220072021
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: August 11, 2021
    Publication date: March 10, 2022
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR
    Publication number: 20210353634
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.
    Type: Application
    Filed: February 26, 2021
    Publication date: November 18, 2021
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • Combination formulation of two antiviral compounds
    Patent number: 11116783
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 14, 2021
    Assignee: Gilead Pharmasset LLC
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • Combination formulation of three antiviral compounds
    Patent number: 10912814
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 9, 2021
    Assignee: Gilead Pharmasset LLC
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20210000854
    Abstract: Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: June 16, 2020
    Publication date: January 7, 2021
    Inventors: Eric Gorman, Erik Mogalian, Reza Oliyai, Dimitrios Stefanidis, Lauren Wiser, Vahid Zia
  • COMBINATION FORMULATION OF THREE ANTIVIRAL COMPOUNDS
    Publication number: 20200323894
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 15, 2020
    Applicants: Gilead Pharmasset LLC, Gilead Pharmasset LLC
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • THERAPEUTIC COMPOUNDS
    Publication number: 20200262815
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: November 25, 2019
    Publication date: August 20, 2020
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS
    Publication number: 20200188419
    Abstract: Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Inventors: Ben Chal, Erik Mogalian, Reza Oliyai, Rowchanak Pakdaman, Dimitrios Stefanidis, Vahid Zia
  • Therapeutic compounds
    Patent number: 10654827
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 19, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • CAPSID INHIBITORS FOR THE TREATMENT OF HIV
    Publication number: 20200038389
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 6, 2020
    Applicant: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE48285
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: October 27, 2020
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin
  • N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
    Patent number: RE49445
    Abstract: The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 7, 2023
    Assignee: Sierra Oncology, Inc.
    Inventors: Brandon H. Brown, Ernest A. Carra, Jeffrey N. Hemenway, Henry Morrison, Troy Reynolds, Bing Shi, Dimitrios Stefanidis, Fang Wang, Matthew Robert Warr, James Andrew Whitney, Yan Xin